Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 30

1.

Bone densitometric assessment and management of fracture risk in Indian men of prostate cancer on androgen deprivation therapy: Does practice pattern match the guidelines?

Pradhan MR, Mandhani A, Chipde SS, Srivastava A, Singh M, Kapoor R.

Indian J Urol. 2012 Oct;28(4):399-404. doi: 10.4103/0970-1591.105750.

2.

Bone and metabolic health in patients with non-metastatic prostate cancer who are receiving androgen deprivation therapy.

Grossmann M, Hamilton EJ, Gilfillan C, Bolton D, Joon DL, Zajac JD.

Med J Aust. 2011 Mar 21;194(6):301-6. Review.

PMID:
21426285
3.
4.

Maintaining bone health in patients with prostate cancer.

Holmes-Walker DJ, Woo H, Gurney H, Do VT, Chipps DR.

Med J Aust. 2006 Feb 20;184(4):176-9. Review.

PMID:
16489902
5.

Osteoporosis due to androgen deprivation therapy in men with prostate cancer.

Daniell HW.

Urology. 2001 Aug;58(2 Suppl 1):101-7. Review.

PMID:
11502461
6.

Osteoporosis in men with prostate carcinoma receiving androgen-deprivation therapy: recommendations for diagnosis and therapies.

Diamond TH, Higano CS, Smith MR, Guise TA, Singer FR.

Cancer. 2004 Mar 1;100(5):892-9. Review.

7.

Bone health in men receiving androgen deprivation therapy for prostate cancer.

Eastham JA.

J Urol. 2007 Jan;177(1):17-24. Review.

PMID:
17161994
8.
10.

Bone loss and the evolving role of bisphosphonate therapy in prostate cancer.

Higano CS.

Urol Oncol. 2003 Sep-Oct;21(5):392-8. Review.

PMID:
14670551
11.

Osteoporosis in men treated with androgen deprivation therapy for prostate cancer.

Ross RW, Small EJ.

J Urol. 2002 May;167(5):1952-6. Review.

PMID:
11956415
12.

Background to and management of treatment-related bone loss in prostate cancer.

Berruti A, Tucci M, Terrone C, Gorzegno G, Scarpa RM, Angeli A, Dogliotti L.

Drugs Aging. 2002;19(12):899-910. Review.

PMID:
12495366
13.

GU radiation oncologists consensus on bone loss from androgen deprivation.

Duncan GG, Corbett T, Lukka H, Warde P, Pickles T.

Can J Urol. 2006 Feb;13(1):2962-6.

PMID:
16515750
15.
16.

[Bone loss in men under androgen-deprivation therapy for prostate cancer].

Ishizaka K, Machida T, Yoshida K.

Nihon Rinsho. 2005 Apr;63(4):721-6. Review. Japanese.

PMID:
15828242
17.
18.

Osteoporosis during androgen deprivation therapy for prostate cancer.

Smith MR.

Urology. 2002 Sep;60(3 Suppl 1):79-85; discussion 86. Review.

PMID:
12231056
19.

Review of major adverse effects of androgen-deprivation therapy in men with prostate cancer.

Taylor LG, Canfield SE, Du XL.

Cancer. 2009 Jun 1;115(11):2388-99. doi: 10.1002/cncr.24283. Review.

20.

The role of bisphosphonates in men with prostate cancer receiving androgen deprivation therapy.

Smith MR.

Oncology (Williston Park). 2004 May;18(5 Suppl 3):21-5. Review.

PMID:
15202584

Supplemental Content

Support Center